COVID-19 in the years 2020 to 2022 in Germany: effects of comorbidities and co-medications based on a large-scale database analysis
Abstract Background The SARS-CoV-2 pandemic was a challenge for health care systems worldwide. People with pre-existing chronic diseases have been identified as vulnerable patient groups. Furthermore, some of the drugs used for these chronic diseases such as antihypertensive drugs have been discusse...
Saved in:
Main Authors: | Roland Linder, Jonas Peltner, Anatoli Astvatsatourov, Willy Gomm, Britta Haenisch |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | BMC Public Health |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12889-024-21110-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modern vaccines and coronavirus infections
by: Yu. A. Belikova, et al.
Published: (2020-12-01) -
COVID-19 – a new challenge for the medical community
by: D. Valančius, et al.
Published: (2020-06-01) -
mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development
by: A. A. Ilyichev, et al.
Published: (2020-12-01) -
Ebola Virus and SARS-CoV-2: Similarities and Differences
by: Robert C. SIZEMORE, et al.
Published: (2020-07-01) -
SARS and MERS as learning tools for addressing the 2019-nCoV epidemic: A mini-review
by: Udit DAVE, et al.
Published: (2020-07-01)